ArriVent BioPharma Inc

Arrivent Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in identifying, licensing, and globalizing biopharma innovations from around the world to deliver important medicines to patients. The company is headquartered in Newtown Square, Pennsylvania and currently employs 77 full-time employees. The company went IPO on 2024-01-26. The firm is focused on maximizing the potential of its lead development candidate, firmonertinib, and advancing a pipeline of novel therapeutics, such as antibody drug conjugates (ADCs), through approval and commercialization. Firmonertinib is an oral, highly brain-penetrant, and broadly active mutation-selective epidermal growth factor receptor (EGFR) inhibitor active against both classical and uncommon EGFR mutations, including PACC and exon 20 insertion mutations. Firmonertinib is also being studied in a clinical combination study targeting advanced or metastatic NSCLC patients with EGFR classical mutations. The company is developing ARR-217, an ADC for the treatment of gastrointestinal cancers. Its ARR-002 candidate is focused on the treatment of solid tumors.